Literature DB >> 24517833

Label-free cell phenotypic drug discovery.

Ye Fang1.   

Abstract

Phenotypic screen holds great potential in the discovery of new small molecule probes and drugs, as it permits interrogating small molecules with native targets and pathways in model organisms and disease relevant cells. In recent years, label-free cell phenotypic profiling has emerged as an alternative for drug discovery. This paper provides the rationale for phenotypic screens, discusses the basics of label-free cell phenotypic profiling technologies, and provides some guidelines as to how to use these techniques to facilitate drug discovery.

Mesh:

Year:  2014        PMID: 24517833     DOI: 10.2174/1386207317666140211100000

Source DB:  PubMed          Journal:  Comb Chem High Throughput Screen        ISSN: 1386-2073            Impact factor:   1.339


  5 in total

Review 1.  Impedance-based cellular assays for regenerative medicine.

Authors:  W Gamal; H Wu; I Underwood; J Jia; S Smith; P O Bagnaninchi
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-07-05       Impact factor: 6.237

Review 2.  The Purinosome: A Case Study for a Mammalian Metabolon.

Authors:  Anthony M Pedley; Vidhi Pareek; Stephen J Benkovic
Journal:  Annu Rev Biochem       Date:  2022-03-23       Impact factor: 27.258

Review 3.  Total internal reflection fluorescence quantification of receptor pharmacology.

Authors:  Ye Fang
Journal:  Biosensors (Basel)       Date:  2015-04-27

Review 4.  Three-Dimensional Cell Cultures in Drug Discovery and Development.

Authors:  Ye Fang; Richard M Eglen
Journal:  SLAS Discov       Date:  2017-06       Impact factor: 3.341

5.  Label-free toxicology screening of primary human mesenchymal cells and iPS-derived neurons.

Authors:  Maria Serena Piccinno; Tiziana Petrachi; Elisa Resca; Valentina Strusi; Valentina Bergamini; Giuseppe Antonio Mulas; Giorgio Mari; Massimo Dominici; Elena Veronesi
Journal:  PLoS One       Date:  2018-09-04       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.